XM does not provide services to residents of the United States of America.
G
G

Gilead

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Paramount Global PARA.OQ +6.9% First Solar Inc FSLR.OQ +6.6% Tesla Inc TSLA.OQ +6.5% Vistra Corp VST.N +4.6% NVIDIA Corp NVDA.OQ +4.6% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Constellation Brands Inc
G
N
T
W
U

Cellares Kite, A Gilead Company, Will Evaluate Co's Automated Manufacturing Platform Cell Shuttle

BRIEF-Cellares Kite, A Gilead Company, Will Evaluate Co's Automated Manufacturing Platform Cell Shuttle June 27 (Reuters) - Gilead Sciences Inc GILD.O : CELLARES: KITE, A GILEAD COMPANY, WILL EVALUATE CO'S AUTOMATED MANUFACTURING PLATFORM CELL SHUTTLE Source text for Eikon: ID:nBw10TJNsa Further company coverage: GILD.O
G

U.S. stocks weekly: Heat advisory

RPT-BUZZ-U.S. stocks weekly: Heat advisory Repeats from Friday with no changes to text. Updates chart ** S&P 500 .SPX gains third consecutive week, advances 0.6% .N ** Indeed, benchmark index heating up just as summer solstice hits ** And Nasdaq .IXIC ekes out third-straight weekly gain, though it may be flying on fumes ** Most sectors toasty; Consumer Discretionary and Energy bake most, while Tech and bond-proxies cool off; this, as Growth .IGX was on pace for its best month vs Value .IVX in 24
A
A
G
M
N
U
U

U.S. CarMax, Eli Lilly, MicroStrategy

U.S. RESEARCH ROUNDUP-CarMax, Eli Lilly, MicroStrategy June 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CarMax, Eli Lilly and MicroStrategy, on Monday. HIGHLIGHTS * CarMax Inc KMX.N : RBC raises target price to $75 from $73 * Eli Lilly LLY.N : Jefferies raises target price to $1,015 from $994 * MicroStrategy Inc MSTR.O : Canaccord Genuity cuts target price to $1,826 from $2,047 * Sharecare Inc SHCR.O : Canacco
A
A
B
D
G
M
N
V
E
F
T
E
P
R
T
C
C
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.